Merck & Co., Inc. (NYSE:MRK) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Merck & Co., Inc. (NYSE:MRK) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-seven brokerages that are presently covering the firm, Marketbeat reports. Ten investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $151.32.

Several equities analysts have weighed in on the stock. Jefferies Financial Group raised their target price on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Sanford C. Bernstein lifted their target price on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a “market perform” rating in a research report on Tuesday, August 4th. Bank of America upped their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Scotiabank increased their price target on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company a “sector outperform” rating in a research report on Tuesday, September 29th. Finally, Morgan Stanley lowered their price target on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating on the stock in a research report on Wednesday.

Merck & Co., Inc. Stock Up 2.2%

Merck & Co., Inc. stock opened at $145.52 on Tuesday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The firm has a market capitalization of $359.03 billion, a price-to-earnings ratio of 116.42, a price-to-earnings-growth ratio of 6.55 and a beta of 0.21. Merck & Co., Inc. has a fifty-two week low of $82.01 and a fifty-two week high of $156.92. The stock’s fifty day moving average is $143.90 and its two-hundred day moving average is $128.28.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter last year, the business posted $2.13 earnings per share. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts predict that Merck & Co., Inc. will post 2.66 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is currently 272.00%.

Insider Activity

In related news, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the sale, the executive vice president owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

Hedge funds have recently modified their holdings of the company. Susquehanna Fundamental Investments LLC acquired a new position in Merck & Co., Inc. during the second quarter valued at approximately $11,470,000. Russell Investments Group Ltd. increased its position in shares of Merck & Co., Inc. by 2.0% in the second quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company’s stock worth $331,931,000 after acquiring an additional 51,393 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Merck & Co., Inc. by 7.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,184,340 shares of the company’s stock worth $794,577,000 after acquiring an additional 402,011 shares in the last quarter. Talon Private Wealth LLC acquired a new stake in shares of Merck & Co., Inc. in the second quarter worth $995,000. Finally, Panagora Asset Management Inc. raised its stake in shares of Merck & Co., Inc. by 410.5% in the 4th quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company’s stock valued at $74,255,000 after acquiring an additional 567,249 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck is participating in a broad rally across biotechnology and vaccine stocks, providing sector-wide momentum for MRK shares. Novavax Soars, Moderna Surges, Merck Climbs as Biotech Rallies
• Positive Sentiment: The FDA approved Merck’s WELIREG plus LENVIMA combination for adults with advanced kidney cancer previously treated with PD-1 or PD-L1 therapies. The approval expands Merck’s oncology opportunity beyond its core Keytruda franchise. Merck also started a Phase I trial involving Cyprumed’s oral peptide-delivery platform, adding a potential pipeline catalyst. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
• Positive Sentiment: Cantor Fitzgerald raised its Merck price target to $145 from $120, while Morgan Stanley maintained or issued a Buy view in separate coverage. These actions suggest some analysts see the recent weakness and long-term growth prospects as attractive. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
• Neutral Sentiment: Apella Capital increased its Merck position by 16.6% to 43,902 shares. The purchase indicates institutional confidence, although the position is too small to materially affect Merck’s fundamentals. Apella Capital Increases Stake in Merck
• Negative Sentiment: A Dutch court blocked Merck’s planned subcutaneous Keytruda product in eight European markets amid a patent dispute with Halozyme. The ruling could delay a potentially important reformulation and complicate efforts to extend Keytruda’s commercial life. HALO Wins Court Order Blocking Merck’s Keytruda SC in Europe
• Negative Sentiment: Merck is viewed as one of the pharmaceutical companies most exposed to upcoming patent losses and generic competition, raising longer-term concerns about revenue after Keytruda’s exclusivity period. Analysts have also flagged mixed growth prospects, while Morgan Stanley issued a separate pessimistic forecast. Pharma’s $500 Billion Patent Problem Will Come in Waves

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.